Skip to main content

Table 2 Characteristics of patients who underwent surgical resection (n = 13)

From: Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer

  No. (%)
Age (years)
 Median 50.5 (IQR 41–57)
Gender
 Male 9 (69.2)
 Female 4 (30.8)
ECOG PS
 One 9 (69.2)
 Two 4 (30.8)
Sidedness of the primary tumor
 Right 3 (23.1)
 Left 10 (76.9)
Number of organs involved
 Median 1
 Range (1–2)
 One 8 (61.5)
 Greater than one 5 (38.5)
Site of metastasis
 Liver 5 (38.5)
 Lung 1 (7.7)
 LNs 6 (46.2)
 Peritoneum 5 (38.5)
KRAS gene mutation
 Mutant 7 (53.8)
 Wild-type 5 (38.5)
 Unknown 1 (7.7)
Best response to XELOXIRI/A
 CR 1 (7.7)
 PR 10 (76.9)
 SD 2 (15.4)
Surgical resection margin  
 R0 10 (76.9)
 R1 3 (23.1)
  1. IQR interquartile range; XELOXIRI/A xeloda, oxaliplatin, irinotecan, and avastin; ECOGPS Eastern Cooperative Oncology Group Performance Status; CR complete response; PR partial response; SD stable disease; Primary primary tumor resection